Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVN766 SAD/MAD in Healthy Subjects
NCT05105243Phase 1Completed
- Sponsor
- Cerevance
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CVN766 in schizophrenia and binge eating disorder (BED) (8 cohorts), sponsored by Cerevance. Primary endpoints: Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event, Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters and 2 more. Started Jan 2022; status: completed.
02
Drugs
CVN766
03
Conditions
schizophreniabinge eating disorder (BED)
Beyond the preview
Go deeper on NCT05105243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105243.